Compare Home Depot Inc (HD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs ResMed Inc. — how do they compare? Home Depot Inc trades at $291.64 (market cap $294.79B), while ResMed Inc. trades at $229.75 (market cap $31.89B). The key difference: Home Depot Inc is far larger — about 9.2× ResMed Inc.'s market cap, and Home Depot Inc pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and ResMed Inc. for 51 Days on average.
| HD | RMD | |
|---|---|---|
Market Cap | $294.79B | $31.89B |
Volume | 8,693,917 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $277.88 |
52-Week Low | $281.15 | $182.82 |
Typical Hold Time | 139 Days | 51 Days |
Enterprise Value | $355.27B | $31.24B |
Dividend Yield | 3.15% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $291.17, up 1.89% today, with a bullish technical signal but mixed moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.92 exceeding expectations. Revenue for 2025 reached $159.51 billion, though net income margin has trended down to 8.41%. Analyst consensus is bullish with a $379.93 price target, but rising mortgage rates and weak big-ticket demand pose headwinds.
The outlook remains cautiously optimistic given HD's robust profitability and Pro business growth, but margin pressure and housing market sensitivity are key risks. Institutional activity shows mixed positioning, with some firms increasing stakes while others trim holdings. The stock's valuation at a P/E of 20.68 appears reasonable if earnings momentum continues.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
